Marshall Wace’s Atea Pharmaceuticals AVIR Stock Holding History

Marshall Wace’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-113,585	Closed	-$405K	–	3187
2025 Q4	$405K	Buy	113,585 +26,525	+30%	+$84.3K	﹤0.01%	2326
2025 Q3	$252K	Buy	87,060 +62,193	+250%	+$212K	﹤0.01%	2490
2025 Q2	$89.5K	Buy	+24,867	New	+$74.2K	﹤0.01%	2556
2025 Q1	–	Sell	-77,581	Closed	-$260K	–	2624
2024 Q4	$260K	Buy	+77,581	New	+$258K	﹤0.01%	2278
2024 Q3	–	Sell	-182,326	Closed	-$603K	–	2493
2024 Q2	$603K	Buy	+182,326	New	+$680K	﹤0.01%	1899
2023 Q3	–	Sell	-33,674	Closed	-$126K	–	2180
2023 Q2	$126K	Buy	+33,674	New	+$126K	﹤0.01%	2299
2022 Q1	–	Sell	-4,949	Closed	-$44K	–	3342
2021 Q4	$44K	Sell	4,949 -334,604	-99%	-$5.21M	﹤0.01%	3580
2021 Q3	$11.9M	Buy	339,553 +240,847	+244%	+$6.68M	0.05%	463
2021 Q2	$2.12M	Buy	+98,706	New	+$2.97M	0.01%	1380

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace's AVIR Position: Q1 2026 in Review

Marshall Wace sold out of Atea Pharmaceuticals (AVIR) in Q1 2026, closing a stake of 113,585 shares — an estimated $405K sold.

Marshall Wace first reported a position in AVIR in Q2 2021 and held it in 9 quarters. The position peaked at $11.9M in Q3 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

Marshall Wace reported no remaining Atea Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Marshall Wace sold 113,585 Atea Pharmaceuticals shares in Q1 2026, an estimated $405K.
Marshall Wace first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 9 quarters.
Marshall Wace's Atea Pharmaceuticals position peaked at $11.9M in Q3 2021.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.